Pimasertib hydrochloride/Pilaralisib

N/A

Report date: 2022/01/29 17:55:22

Base Information

Drug NamePimasertib hydrochloride/Pilaralisib

Drug Alias NamePilaralisib+Pimasertib hydrochloridePimasertib hydrochloride+PilaralisibPilaralisib/Pimasertib hydrochlorideAS-703026/XL-147SAR-245408/XL-147 +[7]

ClassificationSmall molecules

Mechanisms of ActionPI3-kinase class I inhibitorsDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors

TargetsDual specificity mitogen-activated protein kinase kinase 2PI3-kinase class IDual specificity mitogen-activated protein kinase kinase 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Pilaralisib Pimasertib hydrochloride

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSanofi Merck Serono

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSanofi Merck Serono

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A